In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Cellular immunotherapy researchers have long been focused on tumor infiltrating lymphocytes (TILs). These naturally occurring anti-cancer cells fight—from inside the tumor—against malignant cells. TIL Cell Therapy is currently being evaluated in clinical trials and encouraging study results have been presented and published.
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond, where cellular immunotherapy fits into the expanding range of cancer immunotherapies, and what community providers need to know.
Mark Faries, MD
Co-director, Melanoma Program and Head of Surgical Oncology
The Angeles Clinic & Research Institute
Los Angeles, CA
“I think TIL [Cell Therapy] as it’s currently being tested in the clinical setting is just the tip of the iceberg, and that we will get much better at refining these treatments as they become more widely used."
Sigrun Hallmeyer, MD
Medical Director, Advocate Lutheran General Hospital Cancer Service Line
Medical Director, Advocate Lutheran General Hospital Cancer Survivorship Program
Co-Director, Medical Research, Advocate AuroraHealth
Park Ridge, IL
“What is exciting to me is that we have really understood how the patient’s immune system (how the human immune system) really has capabilities of recognizing and ultimately eradicating malignancies."
To learn more about this education program, please visit the Preparing for New Cellular Therapies: Tumor-Infiltrating Lymphocytes webpage. This project is supported by Iovance Biotherapeutics.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
